SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be available on the conference website beginning at 7 a.m. Eastern / 4 a.m. Pacific on January 10, 2022.
Related Articles

Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that two presentations with patient data on indicators of efficacy in the treatment of gastrointestinal disorders… Click here to view original post… […]

Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock. Each share… Click here to view original post… […]

Progenity Announces Closing of $40 Million Underwritten Public Offering
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock, at a… Click here to view original post… […]